NIH A1 Resubmission Strategy: How to Turn a Score Into an Award

What Changes When You Go from A0 to A1

The first submission of an NIH grant goes into review with no feedback history. Reviewers have only your application and whatever they know about the field. The resubmission — the A1 — is fundamentally different. Reviewers will have your original application, the summary statement from the prior review, and your revised application all in front of them. That sounds like an advantage, and it is. But it also means every change you make will be judged against what you said before, and every criticism you fail to address will look like a deliberate choice rather than an oversight.

NIH policy allows exactly one resubmission of a given application. You have 37 months from the original due date to submit it. If the A1 is also unsuccessful, you can start fresh with a second A0 — more on that path later — but the A1 gets one shot. This constraint matters for how you approach the revision. You can't hold back improvements for a hypothetical A2 that doesn't exist. Everything you have goes in this time.

The most important thing that changes between A0 and A1 is that you're no longer guessing what reviewers think. The summary statement tells you exactly where the three assigned reviewers had concerns, what their criterion scores were, and often gives you the verbatim phrases they expect to see addressed. Applicants who don't use that information fully are squandering the biggest structural advantage a resubmission has over a first submission.

Reading Your Summary Statement Before You Write a Single Word

Before you revise a single sentence, spend at least a week with the summary statement. Print it, annotate it, and sort every critique into two categories: structural and tactical. Structural criticisms go to the heart of the proposal — the significance of the problem, the logic of the aims, the plausibility of the central hypothesis. Tactical ones are about execution — a missing control, a reagent that needs validation, a collaborator whose credentials should be spelled out. These two types require very different responses, and conflating them is the most common planning error I see in resubmission applications.

Structural criticisms need structural fixes. If two reviewers say the gap you're addressing isn't clearly a gap, rewriting the background section won't fix that. The problem statement in the Specific Aims page has to change. If the concern is that Aim 2 is contingent on Aim 1, you have to restructure the aims themselves, not just explain in the Research Strategy why the dependency is acceptable. Reviewers who raised a structural concern will return to the resubmission looking specifically for whether the structure changed. A cosmetic revision signals that you didn't understand the problem.

Tactical criticisms are more forgiving. Adding a control experiment, providing a figure showing that your antibody works in the species you propose to use, or adding a biostatistician to the team — these are the kinds of changes a two-paragraph introduction response can credibly address. The trap is spending all your revision energy on tactical fixes while leaving structural problems untouched, then wondering why the score didn't move.

Also read the unscored observations. Reviewers sometimes include comments that didn't directly affect the criterion scores but reflect the Study Section's general reaction. If three reviewers say a version of the same thing in their unscored sections, that's a consensus signal worth acting on even if it wasn't the primary driver of a weak score.

Writing the Introduction Page: One Page, No Wasted Lines

The introduction page is the only section of an NIH application that explicitly exists to address previous reviewers. It's also the first thing a reviewer reads when they open your A1. That means it sets the tone for the entire second review — and it has exactly one page to do it.

NIH requires the introduction to summarize substantial additions, deletions, and changes, and to respond to the issues raised in the summary statement. What the policy doesn't say explicitly, but what every experienced reviewer will tell you, is that the introduction should never argue. Reviewers who feel lectured or contradicted will harden, not soften. Your job on this one page is to show that you heard the criticism, explain what you changed in response, and point the reviewer to where they can verify the change in the application.

Keep the language clean even when a reviewer was clearly wrong about something. The phrase "we respectfully disagree" may feel necessary, but it rarely helps and sometimes hurts. Instead, provide the data or citation that answers the concern and let the reviewer reach their own conclusion. Reviewers who feel they've been proven wrong by evidence will usually adjust. Reviewers who feel lectured will not.

What to Change, What to Keep, and What Not to Explain

Managing Reviewer Skepticism at Your Second Review

You may get the same assigned reviewers for your A1 that reviewed your A0, or you may get a completely different panel. NIH doesn't guarantee either. If the same reviewers return, they'll compare your revision against their prior comments in detail. If new reviewers are assigned, they'll read your introduction as their primary guide to what changed and why. Both audiences have to be served by the same document — that's the real constraint the one-page limit imposes.

For returning reviewers, the introduction needs to show you took their specific feedback seriously. For new reviewers, it needs enough context to understand why this is a materially different application, not just a polished version of the original. One practical approach: write the introduction as if all reviewers are new and have no prior context. Then go back and make sure each named criticism is traceable to the prior summary statement. This order of operations prevents the common failure of an introduction that's opaque to anyone who hasn't memorized the original application.

It's also worth contacting your program officer before you submit. A brief conversation after your summary statement arrives can tell you whether the prior score was in a fundable range at your target institute, whether the concerns raised were the kind of concerns that tend to resolve in a revision, and whether there's any change in the landscape — payline shifts, new priorities, or a related FOA — that should influence how you frame the resubmission. That conversation costs 15 minutes and sometimes changes the entire approach.

If the A1 Fails: The Second A0 Path

If your A1 isn't funded, you can submit a second A0. This is less well understood than it should be. NIH doesn't require you to demonstrate substantial changes in scientific direction — NIH explicitly dropped that requirement years ago. You can submit essentially the same research plan as a new application. What you cannot do is include an introduction responding to prior critiques. If you do, the application will be returned without review. The review panel won't know prior submissions exist, and you can't tell them.

This means you improve the application using everything you learned from two rounds of peer review, but you do it silently. Sharper aims, new preliminary data, cleaner writing — all of this is fair game. Crediting the changes to prior reviewer feedback is not. Think of it as starting a fresh conversation with the Study Section, using everything the last two conversations taught you.

The second A0 is most worth pursuing when: the prior scores were in or near the fundable range and the criticism was primarily tactical; the field has shifted in a direction that strengthens your case; or you have substantially new preliminary data that changes the shape of the project. It's less worth pursuing when structural criticisms — the significance of the problem, the logic of the aims — were raised repeatedly without being fully resolved. That's usually a signal that the framing of the project needs a more fundamental rethink, not just better experiments. NIAID has published data suggesting that second A0 applications following an unsuccessful A1 succeed at rates comparable to first-time A0 submissions at similar impact scores. It's a legitimate path that many funded investigators have used.

Frequently Asked Questions